Skip to main content

Want a detailed portfolio tracker?

GRAL
NASDAQ
$68.91

GRAIL Inc (GRAL)

GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Website: https://grail.com
68 analysts
Buy
Target: $70.12 (+1.76%)

Market Cap

$3.06B

Free Cash Flow Yield

-9.56%

Beta (5Y)

2.22

Price Chart

Valuation
Market Cap$3.06B
P/S20.44
P/B1.25
Profitability
Total Revenue (TTM)$156M
Gross Profit (TTM)$77M
EBITDA-$527M
Profit Margin-253.2%
Operating Margin-332.9%
EPS-$10.35
Financial Health
Free Cash Flow Yield-9.56%
Growth & Risk
Beta (5Y)2.22
Sharpe Ratio1.18